EGFR p.L858R

About

Gene context: EGFR

Biomarker Type: Somatic Variant

Present: True

Chromosome: 7

Start Position: 55259515

End Position: 55259515

Reference Allele: T

Alternate Allele: G

Cdna Change: c.2573T>G

Protein Change: p.L858R

Variant Annotation: Missense

Exon: 21

Rsid: rs121434568

Hgvsg: 7:g.55259515T>G


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Dacomitinib
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Erlotinib
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Gefitinib
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Osimertinib
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Osimertinib
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Cisplatin, Osimertinib, Pemetrexed
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Carboplatin, Osimertinib, Pemetrexed
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Erlotinib, Ramucirumab
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Osimertinib
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Amivantamab, Lazertinib
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Amivantamab, Lazertinib
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Bevacizumab, Erlotinib
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Osimertinib
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Cisplatin, Osimertinib
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Carboplatin, Osimertinib
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Osimertinib